Sabby Management LLC has recently announced that it has increased stake in TransCode Therapeutics Inc (NASDAQ:RNAZ) by 32.83%. After grabbing 0.25 million shares, the institutional investor is now in possession of 61872.0 shares of the Healthcare Company. The new investment brought the stake of investor firm to 1.25% having worth around $92614.0. Moreover, UBS Securities LLC increased its share by 0.15 million to have a control over 0.15 million shares. And Tang Capital Management LLC raised its holdings to 84010.0 shares by acquiring 84010.0 shares or 0.42% of the stake.
TransCode Therapeutics Inc (RNAZ) concluded trading on 11/30/23 at a closing price of $0.25, with 32.61 million shares of worth about $8.15 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -93.77% during that period and on Thursday the price saw a loss of about -1.20%. Currently the company’s common shares owned by public are about 20.10M shares, out of which, 19.70M shares are available for trading.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
According to filings with the U.S. Securities and Exchange Commission (SEC), insiders took part in trade of the company’s stock for 5 times over the past 12 months. They bought 184,957 shares in 5 of the transactions. In 0 selling transactions, insiders dumped 0 shares.
Fidelity Extended Market Index Fu, Fidelity Nasdaq Composite Index F, and Fidelity Series Total Market Inde are the top 3 mutual funds which are holding stakes in TransCode Therapeutics Inc Fidelity Extended Market Index Fu is currently holding 8358.0 shares of worth totaling $3092.0. The company recently came buying 5729.0 shares which brought its stake up to 0.04% of the company’s outstanding shares. Fidelity Series Total Market Inde, after buying 198.0 shares, have now control over 0.00% of the stake in the company. It holds 0.0 shares of worth $73.0.
TransCode Therapeutics Inc (NASDAQ: RNAZ) started trading at $0.28, above $0.03 from concluding price of the previous day. However, the stock later moved at a day high price of 0.4620, or with a loss of -1.20%. Stock saw a price change of 0.49% in past 5 days and over the past one month there was a price change of -33.55%. Year-to-date (YTD), RNAZ shares are showing a performance of -98.17% which decreased to -97.13% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.15 but also hit the highest price of $23.40 during that period. The average intraday trading volume for TransCode Therapeutics Inc shares is 6.44 million. The stock is currently trading -17.80% below its 20-day simple moving average (SMA20), while that difference is down -44.46% for SMA50 and it goes to -93.19% lower than SMA200.
Sabby Management LLC acquired 0.25 million shares of TransCode Therapeutics Inc having value of about $92614.0. Data submitted at the U.S SEC by Sabby Management LLC revealed that the firm now holds 61872.0 shares in the company valued at close to $15468.0, or have control over 32.83% stake in the company. TransCode Therapeutics Inc (NASDAQ: RNAZ) currently have 20.10M outstanding shares and institutions hold larger chunk of about 2.79% of that. Holding of mutual funds in the company is about 1.18% while other institutional holders and individual stake holders have control over 2.74% and 0.05% of the stake respectively.
The stock has a current market capitalization of $4.94M and its 3Y-monthly beta is at -0.29. It has posted earnings per share of -$19.57 in the same period. It has Quick Ratio of 1.67 while making debt-to-equity ratio of 0.13. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for RNAZ, volatility over the week remained 28.42% while standing at 19.25% over the month.
Analysts are in expectations that TransCode Therapeutics Inc (RNAZ) stock would likely to be making an EPS of -$0.27 in the current quarter, while forecast for next quarter EPS is $0 and it is -$0.63 for next year. For the current quarter EPS, analysts have given the company a lowest target -$0.27 which is -$0.27 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -$6.6 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 79.37% while it is estimated to increase by 88.69% in next year.
Analysts at 1 brokerage firms have issued recommendations for the TransCode Therapeutics Inc (RNAZ)’s stock and average of those rates the stock at a “Strong Buy” and assign it a score of 1.00. Out of those 1 Wall Street analysts, 1 recommended a “Buy” rating, while 0 were in favor recommending the stock as a “Hold” and 0 analyst recommended the stock as “Sell”.
